Marc Carrier/X
Apr 13, 2026, 12:48
Marc Carrier: The Vermont Model Demonstrates the Power of VTE Prevention
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared a post on LinkedIn about a recent article by Chris Holmes et al, published in JCO Oncology Practice:
”Real-world evidence confirms what trials have shown: guideline-based VTE prevention matters.
In high-risk ambulatory cancer patients, a multidisciplinary program (‘Vermont model‘) led to:
- VTE: 3.2% vs 7.7% (OR 0.36)
- 6-month mortality: 16.8% vs 31.3% (OR 0.46)
- Despite strong evidence, uptake remains suboptimal, closing this gap is an immediate opportunity to improve outcomes in cancer care.”
Title: Impact of Venous Thrombosis Prevention in Ambulatory Oncology: Importance of Guideline Adherence
Authors: Chris Holmes, Karlyn Martin, Derek Devine, Jacob Barker, Peter Callas, Karen Libby, Emily Parenteau, Mary Cushman, Steven Ades
Read the Full Article on JCO Oncology Practice
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 13, 2026, 02:01Nour Al-Mozain: Is It Really Anti-D? – Unraveling Auto-Anti-LW in the Transfusion Laboratory
-
Oct 13, 2026, 01:51Berenice Villegas: The Role of Morphologic Evaluation in Body Fluid Differential Analysis
-
Oct 13, 2026, 01:44Debadrita Ray: Evaluating vWF and VITRO Score for Detecting CSPH in cACLD Patients
-
Oct 13, 2026, 01:34Nagesh Ramesh: Donating Blood for International Plasma Awareness Week
-
Oct 12, 2026, 21:51Sam Botchey: Orthobiologics Are Advancing but the Evidence Must Keep Pace
-
Oct 12, 2026, 21:50Serum Vitamin D, Platelet Function, and Bleeding in Primary ITP – Platelets Journal
-
Oct 12, 2026, 21:30Nika Samadzadeh Tabrizi: Looking Forward to the PACeS Trial on Anticoagulation for POAF
-
Oct 12, 2026, 21:28Michael Megaly: Does Coronary Ectasia Affect Outcomes in Acute Coronary Syndromes?
-
Oct 12, 2026, 21:25Vitor Borin P. de Souza: Think Twice Before Anticoagulating an Isolated Subsegmental PE